Teresa Helsten, MD
Hematology & Oncology · la Jolla, CANPI 1265408678
Payments from drug & device makers
What this record shows
This record is dominated by education: $12 of the $12 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Gilead. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 1 payment — averaging $11.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$12
Across 52 payments — averaging $18,387 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$718K
- Eli Lilly$100K
- E.r. Squibb & Sons, L.L.C.$84K
- Bayer$22K
- Novartis$21K
- Pfizer$12K
What the payments were for
- Education$12100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $12 |
How this compares
$12 in reported general payments places this provider in the 0th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 65 | $901,262 |
| IbrancePalbociclib | 46 | $696,292 |
| VerzenioAbemaciclib | 29 | $428,359 |
| EliquisApixaban | 21 | $13,281 |
| VeozahFezolinetant | 16 | $8,398 |
| Anastrozole | 104 | $1,770 |
| Letrozole | 78 | $1,550 |
| Exemestane | 22 | $1,286 |
| Oxycodone Hcl | 21 | $449 |
| Tamoxifen Citrate | 14 | $324 |
| Ondansetron OdtOndansetron | 24 | $245 |
| Pregabalin | 15 | $227 |
| Prochlorperazine Maleate | 15 | $139 |
| Famotidine | 11 | $124 |
| Gabapentin | 14 | $55 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in la Jolla
- Alan Savenla Jolla$323K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.